Audentes Therapeutics Inc (BOLD) CEO Matthew R. Patterson Sells 12,952 Shares

Share on StockTwits

Audentes Therapeutics Inc (NASDAQ:BOLD) CEO Matthew R. Patterson sold 12,952 shares of the stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $40.00, for a total transaction of $518,080.00. Following the transaction, the chief executive officer now owns 12,952 shares of the company’s stock, valued at approximately $518,080. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

BOLD traded up $0.56 on Friday, reaching $27.69. The company had a trading volume of 1,699,736 shares, compared to its average volume of 424,443. The company has a market capitalization of $1.48 billion, a P/E ratio of -8.14 and a beta of 0.73. Audentes Therapeutics Inc has a 52-week low of $24.51 and a 52-week high of $46.18.

Audentes Therapeutics (NASDAQ:BOLD) last announced its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.07). As a group, research analysts anticipate that Audentes Therapeutics Inc will post -3.33 EPS for the current year.

A number of equities analysts have weighed in on the stock. Chardan Capital began coverage on shares of Audentes Therapeutics in a research report on Monday, June 25th. They set a “neutral” rating and a $35.00 target price for the company. Zacks Investment Research upgraded shares of Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a research report on Tuesday, July 10th. BidaskClub upgraded shares of Audentes Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, September 18th. HC Wainwright set a $40.00 price objective on shares of Audentes Therapeutics and gave the company a “buy” rating in a research report on Tuesday, September 25th. Finally, B. Riley began coverage on shares of Audentes Therapeutics in a research report on Friday, September 7th. They issued a “sell” rating and a $20.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $35.45.

A number of institutional investors and hedge funds have recently made changes to their positions in BOLD. Tortoise Investment Management LLC purchased a new position in shares of Audentes Therapeutics during the first quarter worth approximately $112,000. Partner Investment Management L.P. purchased a new position in shares of Audentes Therapeutics during the second quarter worth approximately $162,000. Cubist Systematic Strategies LLC purchased a new position in shares of Audentes Therapeutics during the first quarter worth approximately $204,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Audentes Therapeutics during the second quarter worth approximately $226,000. Finally, Quantitative Systematic Strategies LLC purchased a new position in shares of Audentes Therapeutics during the second quarter worth approximately $231,000. 96.74% of the stock is currently owned by institutional investors and hedge funds.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Article: Initial Public Offering (IPO)

Insider Buying and Selling by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply